Plasmacytoid dendritic cells lead the charge against tumors

Immunization of Malignant Melanoma Patients with Full-Length NY-ESO-1 Protein Using TLR7 Agonist Imiquimod as Vaccine Adjuvant

(2014) S. Adams et al.   JOURNAL OF IMMUNOLOGY

Imiquimod clears tumors in mice independent of adaptive immunity by converting pDCs into tumor-killing effector cells

(2012) Barbara Drobits et al.   JOURNAL OF CLINICAL INVESTIGATION

CCR6/CCR10-mediated plasmacytoid dendritic cell recruitment to inflamed epithelia after instruction in lymphoid tissues

(2011) V. Sisirak et al.   BLOOD

Toll-like Receptors and Their Crosstalk with Other Innate Receptors in Infection and Immunity

(2011) Taro Kawai et al.   IMMUNITY

Treatment of Locally Recurrent Mucosal Melanoma With Topical Imiquimod

(2011) Elizabeth C. Smyth et al.   JOURNAL OF CLINICAL ONCOLOGY

Host type I IFN signals are required for antitumor CD8+T cell responses through CD8α+dendritic cells

(2011) Mercedes B. Fuertes et al.   JOURNAL OF EXPERIMENTAL MEDICINE

CCL2 recruits inflammatory monocytes to facilitate breast-tumour metastasis

(2011) Bin-Zhi Qian et al.   NATURE

Toll-Like Receptor Agonists

(2010) Sacha Gnjatic et al.   CANCER JOURNAL

In Situ Vaccination With a TLR9 Agonist Induces Systemic Lymphoma Regression: A Phase I/II Study

(2010) Joshua D. Brody et al.   JOURNAL OF CLINICAL ONCOLOGY

Trafficking properties of plasmacytoid dendritic cells in health and disease

(2010) Silvano Sozzani et al.   TRENDS IN IMMUNOLOGY

Human squamous cell carcinomas evade the immune response by down-regulation of vascular E-selectin and recruitment of regulatory T cells

(2008) Rachael A. Clark et al.   JOURNAL OF EXPERIMENTAL MEDICINE